{"id":"NCT01689532","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-09-21","resultsPosted":"2016-10-27","lastUpdate":"2016-10-27"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"Sirukumab 100 mg","otherNames":[]},{"type":"DRUG","name":"Sirukumab 50 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sirukumab 100 mg","type":"EXPERIMENTAL"},{"label":"Sirukumab 50 mg and Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of sirukumab as a single therapy in Japanese patients with moderately to severely active rheumatoid arthritis (RA) who have not responded to treatment with methotrexate (MTX) or sulfasalazine (SSZ).","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAE)","timeFrame":"Baseline upto Week 68","effectByArm":[{"arm":"Sirukumab 50 Milligram (mg)","deltaMin":56,"sd":null},{"arm":"Sirukumab 100 mg","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":17,"countries":["Japan"]},"refs":{"pmids":["29514712"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":61},"commonTop":["Nasopharyngitis","Injection Site Erythema","Injection Site Swelling","Injection Site Pruritus","Alanine Aminotransferase Increased"]}}